ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company anticipates publication of both data sets as early as the end of 2026. Assuming positive data, the Company plans to assess regulatory and compendia strategies.”